Under Pressure: Sanofi Joins Call For Price Transparency

As Sanofi joined the ranks of pharma companies pledging to limit annual US price increases, the company also released average aggregate list and net prices in 2016, showing net prices declined 2.1%.

The pharmaceutical industry's drug pricing problem isn't going away and some drug manufacturers are realizing that the best way they can address the issue is to be more transparent. Educating legislators and even the public about how US drug pricing and the supply chain work, rebating and discounts, and the differences between net and list prices – and backing those conversations up with hard data – won't, at the very least, erode public perception further.

Transparency is a component of the price pledge SanofiCEO Olivier Brandicourt unveiled May 9. Sanofi vowed to limit annual...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

18 Jun 2025

• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

17 Jun 2025

• By Andy Smith

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

13 Jun 2025

• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.